Decapeptide Combi-Therapy of (resistant) steroidal cancers
Steroid-related cancers have the highest incidence among tumors and its market potential for Europe and U.S.A. is estimated to be at least US$ 2.4 bn p.a. Scientists at the University of Göttingen developed novel proprietary decapeptidic antagonists to target GnRH-II receptor (which is highly expressed in steroidal cancers like e.g. breast, ovarian, endometrium and prostate carcinomas), which could be used in a combination cancer therapy and which potentially could also be used to treat malignant melanoma.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
